G
Greg Jones
Researcher at Research Triangle Park
Publications - 19
Citations - 534
Greg Jones is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Lung cancer & non-small cell lung cancer (NSCLC). The author has an hindex of 7, co-authored 19 publications receiving 311 citations. Previous affiliations of Greg Jones include University of Surrey.
Papers
More filters
Journal ArticleDOI
Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.
N. Guibert,Yuebi Hu,Nora Feeney,Yanan Kuang,Vincent Plagnol,Greg Jones,K. Howarth,J.F. Beeler,Cloud P. Paweletz,Geoffrey R. Oxnard +9 more
TL;DR: The ability of amplicon-based plasma NGS to detect a range of preexisting and acquired resistance mechanisms highlights its potential value as an alternative to single mutation digital PCR- based plasma assays for personalizing treatment of TKI resistance in lung cancer.
Journal ArticleDOI
Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA.
Davina Gale,Andrew R. J. Lawson,Karen Howarth,Mikidache Madi,Bradley Durham,Sarah Smalley,John Calaway,Shannon Blais,Greg Jones,James H. Clark,Peter N. Dimitrov,Michelle Pugh,Samuel Woodhouse,Michael Epstein,Ana Fernandez-Gonzalez,Alexandra S. Whale,Jim F. Huggett,Carole A. Foy,Gerwyn M. Jones,Hadas Raveh-Amit,Karin Schmitt,Alison S. Devonshire,Emma Green,Tim Forshew,Vincent Plagnol,Nitzan Rosenfeld +25 more
TL;DR: These studies demonstrate that eTAm-Seq technology is a robust and reproducible technology for the identification and quantification of somatic mutations in circulating tumor DNA, and support its use in clinical applications for precision medicine.
Journal ArticleDOI
Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling.
Vincent Plagnol,Samuel Woodhouse,Karen Howarth,Stefanie Lensing,Matt Smith,Michael Epstein,Mikidache Madi,Sarah Smalley,Catherine Leroy,Jonathan Hinton,Frank de Kievit,Esther Musgrave-Brown,Colin Herd,Katherine Baker-Neblett,Will Brennan,Peter N. Dimitrov,Nathan Campbell,Clive Morris,Nitzan Rosenfeld,James H. Clark,Davina Gale,Jamie Platt,John Calaway,Greg Jones,Tim Forshew +24 more
TL;DR: Analytical validation demonstrated that the InVisionFirst assay is highly sensitive, specific and robust, and meets analytical requirements for clinical applications.
Journal ArticleDOI
Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Nicolas Guibert,Nicolas Guibert,Greg Jones,John F. Beeler,Vincent Plagnol,Clive Morris,Jean Mourlanette,Myriam Delaunay,Laura Keller,Isabelle Rouquette,Gilles Favre,Anne Pradines,Julien Mazieres +12 more
TL;DR: Targeted sequencing of plasma ctDNA and monitoring its early variations can predict response to ICI in advanced non-small cell lung cancer (NSCLC).
Journal ArticleDOI
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
Biagio Ricciuti,Greg Jones,Mariano Severgnini,Joao Victor Machado Alessi,Gonzalo Recondo,Marissa N. Lawrence,Tim Forshew,Christine A. Lydon,Mizuki Nishino,Michael Cheng,Mark M. Awad +10 more
TL;DR: In this paper, the authors studied the effect of changes in circulating tumor DNA (ctDNA) levels after initiation of first-line pembrolizumab±chemotherapy in non-small cell lung cancer (NSCLC) patients.